Regeneron Pharmaceuticals heads into the final weeks of summer with a 20% one-month rally behind it and options traders turning noticeably more defensive — the sharpest tension in the setup right now.
The clearest signal this week is in the options market. The put/call ratio jumped to 0.944 on Tuesday, more than two standard deviations above its 20-day average of 0.831 — the most defensive options reading for REGN in several months. That spike stands out against a backdrop where the stock has already delivered a strong run, closing at $810.24 and up nearly 2% on the week. When protection-buying accelerates after a big move higher, it often reflects investors locking in gains rather than expressing fresh conviction. The borrow market offers no corroborating pressure: availability is extremely loose, with well over 97 million shares available to borrow and a cost to borrow running below 0.5%. Short interest is a modest 3.5% of free float, barely changed over the past month. Nothing in the lending market suggests shorts are building a meaningful thesis against the stock.
The Street has been scrambling to update targets after Regeneron's strong Q2 print in late July, but the message is mixed rather than uniformly bullish. A broad wave of raises followed the earnings release — Morgan Stanley, Wells Fargo, RBC Capital, Truist, and Cantor Fitzgerald all lifted targets while holding neutral-to-positive ratings. On Monday, Leerink Partners pushed its target to $824 from $641, a sharp move yet still anchored at Market Perform. Guggenheim sits well above the crowd at $1,030 with a Buy. The consensus mean target of $840 implies only modest upside from current levels, and the split between sideline ratings with raised targets and outright bulls with much higher numbers reflects genuine disagreement about where the stock goes from here. The forward EPS growth picture is exceptional — the earnings momentum factor ranks in the 96th percentile for 12-month forward growth — yet the PE of roughly 14x and EV/EBITDA near 8.9x are not demanding multiples for a large-cap biotech at this quality level.
The bear case centres on structural headwinds that a good quarterly print does not resolve. Eylea faces a slow grind of biosimilar erosion, and the failure of fianlimab in metastatic melanoma removed a potential high-value pipeline catalyst. Dupixent competition is intensifying. On the bull side, the EPS revision cycle is clearly running hot, and Dupixent's breadth of indications continues to expand internationally. Dodge & Cox added roughly 413,000 shares through June, and Vanguard Portfolio Management added over 1.4 million — both meaningful accumulation signals from long-duration holders. Against that, Invesco trimmed nearly 140,000 shares in Q1. Insider activity is light and low-significance, with two independent directors selling small lots near $800 on August 10.
The next earnings event is October 30. REGN's last two prints produced day-one moves of roughly 6% and 10% respectively, and five-day follow-throughs of similar magnitude — establishing a pattern of meaningful post-earnings volatility. The question heading into that date is whether the options market's newly elevated put/call ratio reflects hedging of those gains or the start of a broader reassessment as the pipeline picture comes back into focus.
See the live data behind this article on ORTEX.
Open REGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
